Haemonetics (NYSE:HAE) Price Target Raised to $149.00

Haemonetics (NYSE:HAE – Free Report) had its price objective lifted by Citigroup from $123.00 to $149.00 in a research report released on Friday,Benzinga reports. The brokerage currently has a buy rating on the medical instruments supplier’s stock.

Several other equities research analysts have also issued reports on HAE. Weiss Ratings upgraded shares of Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 11th. Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. Raymond James Financial upped their price objective on Haemonetics from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, September 3rd. Mizuho set a $165.00 price objective on Haemonetics in a report on Thursday. Finally, Robert W. Baird raised their target price on Haemonetics from $96.00 to $119.00 and gave the stock an “outperform” rating in a research report on Friday, August 21st. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Haemonetics currently has a consensus rating of “Moderate Buy” and an average price target of $126.38.

Get Our Latest Stock Report on Haemonetics

Haemonetics Stock Performance

HAE stock opened at $119.87 on Friday. The company has a quick ratio of 1.83, a current ratio of 2.84 and a debt-to-equity ratio of 1.24. The firm has a market cap of $5.46 billion, a PE ratio of 53.75, a P/E/G ratio of 2.39 and a beta of 0.62. The business has a 50 day moving average of $111.48 and a 200-day moving average of $80.05. Haemonetics has a 12-month low of $51.00 and a 12-month high of $132.00.

Haemonetics (NYSE:HAE – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.06. The business had revenue of $357.76 million for the quarter, compared to analyst estimates of $345.15 million. Haemonetics had a return on equity of 27.42% and a net margin of 7.52%. Haemonetics’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company posted $1.27 earnings per share. As a group, sell-side analysts expect that Haemonetics will post 5.32 earnings per share for the current year.

Institutional Trading of Haemonetics

Hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC grew its position in Haemonetics by 11.3% during the third quarter. GAMMA Investing LLC now owns 894 shares of the medical instruments supplier’s stock valued at $94,000 after acquiring an additional 91 shares during the last quarter. Abel Hall LLC lifted its holdings in shares of Haemonetics by 4.0% in the 3rd quarter. Abel Hall LLC now owns 3,103 shares of the medical instruments supplier’s stock worth $327,000 after acquiring an additional 119 shares during the last quarter. Fortitude Family Office LLC lifted its holdings in shares of Haemonetics by 104.5% in the 3rd quarter. Fortitude Family Office LLC now owns 272 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 139 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Haemonetics by 12.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 1,920 shares of the medical instruments supplier’s stock valued at $108,000 after purchasing an additional 211 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of Haemonetics by 55.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 946 shares of the medical instruments supplier’s stock valued at $100,000 after purchasing an additional 339 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

More Haemonetics News

Here are the key news stories impacting Haemonetics this week:

  • Positive Sentiment: Quarterly results beat expectations: Haemonetics earned $1.35 per share versus estimates of $1.29 and generated $357.8 million in revenue, above the $345.2 million consensus and up 9.4% year over year. Earnings and outlook report
  • Positive Sentiment: Raised fiscal 2027 outlook: The company increased its full-year revenue and organic-growth outlook, forecasting organic growth of 6%–9%. Fiscal 2027 outlook
  • Positive Sentiment: Analyst price targets rose: Citigroup raised its target to $149 and maintained a Buy rating; Barrington Research lifted its target to $145 with an Outperform rating; and BTIG raised its target to $142 with a Buy rating. Citigroup recommendations
  • Neutral Sentiment: Growth comes with execution considerations: Haemonetics plans to scale the CSL Persona PLUS rollout through calendar 2027, and earnings-call coverage noted growth and margin tradeoffs. This may temper enthusiasm if rollout costs or margins disappoint. Earnings call highlights

About Haemonetics

(Get Free Report)

Haemonetics Corporation is a global medical technology company focused on blood and plasma collection, processing and management. Its products and services are used by plasma collection organizations, blood centers and hospitals.

The company provides automated plasma collection systems and related software and supplies, as well as technologies for collecting and processing blood components. Its hospital offerings include devices for surgical blood salvage and tools that help clinicians assess blood clotting and guide transfusion decisions.

Founded in 1971, Haemonetics serves customers in multiple regions around the world.

Featured Articles

Analyst Recommendations for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.